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Abstract
Background: The consumption of foods containing probiotic and prebiotic ingredients is growing consistently
every year, and in view of the limited number of studies investigating their effect in the elderly.
Objective: The objective of this study was to evaluate the effect of the consumption of a symbiotic shake
containing Lactobacillus acidophilus, Bifidobacterium bifidum and fructooligosaccharides on glycemia and cholesterol
levels in elderly people.
Methods: A randomized, double-blind, placebo-controlled study was conducted on twenty volunteers (ten for
placebo group and ten for symbiotic group), aged 50 to 60 years. The criteria for inclusion in the study were: total
cholesterol > 200 mg/dL; triglycerides > 200 mg/dL and glycemia > 110 mg/dL. Over a total test period of 30
days, 10 individuals (the symbiotic group) consumed a daily dose of 200 mL of a symbiotic shake containing 10
8
UFC/mL Lactobacillus acidophilus,1 0
8 UFC/mL Bifidobacterium bifidum and 2 g oligofructose, while 10 other
volunteers (the placebo group) drank daily the same amount of a shake that did not contain any symbiotic
bacteria. Blood samples were collected 15 days prior to the start of the experiment and at 10-day intervals after
the beginning of the shake intake. The standard lipid profile (total cholesterol, triglycerides and HDL cholesterol)
and glycemia, or blood sugar levels, were evaluated by an enzyme colorimetric assay.
Results: The results of the symbiotic group showed a non-significant reduction (P > 0.05) in total cholesterol and
triglycerides, a significant increase (P < 0.05) in HDL cholesterol and a significant reduction (P < 0.05) in fasting
glycemia. No significant changes were observed in the placebo group.
Conclusion: The consumption of symbiotic shake resulted in a significant increase in HDL and a significant
decrease of glycemia.
Trial Registration: ClinicalTrials.gov: NCT00123456
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Background
At present, cardiovascular diseases are among the major
causes of death in the world. In Brazil, cholesterol is
responsible for nearly 8% of the deaths caused by non-
transmissible diseases, which represents around 4.5 million
people. On the other hand, lipid abnormalities associated
with increased glycemia, or even diabetes, are dangerous
in view of the high vulnerability of these volunteers to cor-
onary diseases [1]. Epidemiological studies show a positive
relation between increased blood sugar levels (glycemia),
lipid dysfunction and cardiovascular diseases [2].
Cardiovascular disease (CVD) is the primary cause of
death in people with type 2 diabetes mellitus (T2DM).
Relative risk of CVD is 2- to 4-fold higher in diabetic
people compared with nondiabetic people [3]. Dyslipide-
mia has been identified as a risk factor for cardiovascu-
lar complications in T2DM. The American Diabetes
Association guidelines indicate that, the primary goal of
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any medium, provided the original work is properly cited.low-density lipoprotein cholesterol (LDL-C) concentra-
tion is less than 2.6 mmol/L (100 mg/dL) in diabetic
people without overt CVD [4].
Probiotic agents are defined as live microorganisms that
when administered in adequate amounts confer health
benefits on the host [5].There are some reports in litera-
ture suggesting or demonstrating that the consumption of
food products containing probiotic microorganisms may
reduce the level of serum cholesterol in humans [6,7]. The
first scientific report associating lactic acid bacteria with a
reduction in serum cholesterol was published in 1974 by
Mann and Spoerry [8], who observed an 18% reduction in
the total serum cholesterol level of warriors of an African
tribe whose regular diet included milk fermented by
lactobacillus.
Prebiotics can be defined as non-digestible food ingredi-
ents that beneficially affect the host by stimulating the
growth and/or activity of one or a limited number of
desired bacteria in the colon, such as bifidobacteria, which
are regarded as beneficial to human health. Although pre-
biotic components primarily act in the large intestine, they
a l s om a yh a v es o m ei m p a c to nm i c r o o r g a n i s m si nt h e
small intestine [9].
The prebiotics identified thus far are non-digestible car-
bohydrates, including lactulose, inulin and several oligo-
saccharides that provide carbohydrates which the colon’s
beneficial bacteria are able to ferment [10]. Some of the
effects attributed to prebiotics include the modulation of
key physiological functions, such as the absorption of cal-
cium, lipid metabolism, glycemia, modulation of the com-
position of the intestinal microbiota - which plays a
primary role in gastrointestinal physiology, and a reduced
risk of colon cancer [11]. There are some reports linking
the consumption of prebiotics to reduced glycemia [10].
The combination of the probiotic and prebiotic might
improve the survival of the bacteria crossing the upper
part of the gastrointestinal tract, thereby enhancing their
effects in the large bowel. In addition, their effects might
be additive or even synergistic [10,11].
As the consumption of foods containing probiotic and
prebiotic ingredients is growing consistently every year,
and in view of the limited number of studies investigating
their effect in the elderly, the objective of this study was to
evaluate the effect of the consumption of a symbiotic
shake containing Lactobacillus acidophilus, Bifidobacter-
ium bifidum and fructooligosaccharides on glycemia and
cholesterol levels in elderly people.
Materials and methods
Production of the symbiotic shake and the placebo shake
The symbiotic shake was developed and manufactured by
the company Maxinutri Alimentos LTDA from a formu-
lation containing 9% skim milk powder (Confepar), 23%
whey powder (Alibra), 21% maltodextrin (Companhia
Lorenz), 15% oatmeal (SL Alimentos), 7% texturized soy-
bean protein TSP (Texpro), 5% soybean fiber (Gama AS),
3.5% guar gum (Doce Aroma), 3.5% collagen (Gelita do
Brasil), 5% soybean extract (San Luca), 4.5% fructooligo-
saccharide (Corns Products), 0.032% sucralose (China),
0.024% acessulfame (China), 0.7% tricalcium phospfate
(China), 2% Lactobacillus acidophilus (Fortitech), 2%
Bifidobacterium bifidum (Fortitech), 1.55% flavor (Doce
aroma), 0.035% sodium chloride (China) and 0.032 cara-
mel color (Corns Products).
All ingredients were added to a Ribbon paddle blender.
In a first stage, a premix was prepared from the ingredi-
ents of greater volume, which individually represent more
than 3% of the total volume of the formulation. The
remaining ingredients were added in small amounts in a
way so as to obtain a homogeneous and uniform blend.
The final blend was filled into plastic containers sealed
with aluminum foil and labeled with information regard-
ing the date of manufacture, expiry date and instructions
on how to prepare the product for consumption. The pla-
cebo shake was manufactured the same way as the sym-
biotic dry mix, but without the addition of the probiotics
Lactobacillus acidophilus and Bifidobacterium bifidum,
nor the prebiotic fructooligosaccharide.
Selection of volunteers
The study was conducted with healthy female individuals,
aged 50-65 years, all living in Arapongas located in the
northern part of the State of Paraná, Brazil. The criteria
for inclusion in the study were: total cholesterol > 200 mg/
dL; triglycerides > 150 mg/dL and glycemia > 110 mg/dL.
All volunteers were taking glucose-lowering medications
however, drug treatment was not able to normalize blood
glucose levels in these volunteers. None were using hypoli-
pidemic agents, antibiotics and minerals or vitamins
supplements.
The selected individuals signed a free informed consent
form and were free to withdraw at any time of the experi-
mental period at their own discretion. The volunteers
were fully informed about the type and purpose of the
study, the expected conduct and all possible risks, reinfor-
cing the importance of not skipping doses or discontinu-
ing the medication in the course of the experiment.
Written informed consent was obtained from the partici-
pants, and the study protocol was approved by the Ethics
in Research Committee of the Universidade Norte do
Paraná (Protocol PP 0186/09).
Clinical characteristics at the baseline of the volun-
teers are presented in Table 1.
Study design and intervention
A 45-day, double-blind, placebo-controlled, randomized
study was conducted on twenty volunteers divided into
two groups (n = 10): Group S (individuals who consumed
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sumed the placebo shake) (NCT00123456; http://www.
clinicaltrials.gov).
The randomization (Figure 1) was conducted and the list
generated by a statistician (TP) not involved in recruit-
ment or study visits, according to computer-generated
block randomization of 10 women to receive shake with
probiotic or shake with placebo. The study was divided
into two periods; pre-ingestion, which volunteers not
ingested symbiotic or placebo product during 15 days and
ingested period, which volunteers ingested during 30 days
the symbiotic or placebo product. During the ingestion
period the volunteers of one group (group S) consumed 2
daily doses of 100 mL symbiotic shake containing 4 × 10
8
UFC/100 mL Lactobacillus acidophillus,4×1 0
8 UFC/100
mL Bifidobacterium bifidum and 1 g/100 mL of fructooli-
gosaccharides. The other group (group P) consumed 2
daily doses of 100 mL shake without added probiotics and
prebiotic. The volunteers were instructed to maintain their
eating habits and physical activity during the study (pre-
ingestion - 15 days; ingestion period - 30 days). Both
groups consumed their respective dietary supplement
shake for a total period of 30 days.
The products were freshly produced every week and
delivered to each volunteer in plastic vials labeled with
t h ed a t eo fm a n u f a c t u r e ,e x p i r yd a t ea n di n s t r u c t i o n s
for preparation and consumption.
Collection of blood samples
At the end of the pre-ingestion period and at every 10
days of the ingestion period the following blood samples
were taken from the volunteers: 1 sample of blood con-
taining anticoagulant (fluoride) for the determination of
glycemia and another blood sample without anticoagulant
for the determination of cholesterol. The volunteers were
asked to fast for at least 8 hours before the blood draw to
prevent possible interference with postprandial lipemia
which in common in non-fasting blood samples. The
plasma was separated from formed elements of the blood
immediately after collection by centrifugation at 2500 rpm
for 10 minutes. Serum was collected after allowing for clot
formation at 37°C in a water bath and subsequent centri-
fugation at 2500 rpm for 10 minutes. Both serum and
plasma were kept at normal refrigerator temperature (2 to
8°C) until analysis [12].
To ensure efficient and reliable performance in analyz-
ing the biochemical parameters, an aliquot of control
serum (Lot number: 40380801/2) - supplied by the Brazi-
lian National Program for Quality Control (Programa
Nacional de Controle de Qualidade PNCQ - SBAC) - was
processed along with the experimental samples at each
test run.
Analysis of serum lipids
Serum total cholesterol and triglycerides levels in the
volunteers blood samples were determined by an
enzyme-colorimetric method (Bio Diagnóstica) using a
semi-automatic apparatus (Bio-plus).
HDL cholesterol was separated based on the selectivity
of the phosphotungstate and magnesium ions which pro-
mote selective precipitation of all lipoproteins (kilomi-
crons, VLDL and LDL), except for the HDL fraction. After
centrifugation, the HDL cholesterol contained in the
supernatant was determined by the same method used for
total cholesterol.
Non-HDL cholesterol was calculated by subtracting
HDL-C from TC and was composed of the LDL + IDL +
VLDL cholesterol fractions.
Analysis of glycemia
Fasting glycemia was determined in the fluoride plasma
of the volunteers by an enzyme-colorimetric method
(Bio Diagnóstica). Glucose oxidase (GOD) catalyzes the
oxidation of glucose to gluconic acid and hydrogen per-
oxidase. Through a peroxidase-catalyzed oxidative cou-
pling reaction (POD), the thus formed hydrogen
peroxide reacts with 4-aminoantipyrin and phenol,
forming a red-colored complex (quinoneimine), the
absorbance of which measured at 500 nm is directly
proportional to the glucose concentration in the blood
sample. Absorbance was determined using a semi-auto-
mated apparatus (Bio-plus), which provides a reading of
the glucose concentration expressed as mg/dL plasma.
Statistical analyses
The results were analyzed by analysis of variance
(ANOVA) and Tukey’s means comparison test using the
STATISTICA 6.0 software program. The differences
were considered significant at the P < 0.05 level of con-
fidence. All data are presented as a mean ± SD.
Table 1 Clinical characteristics at baseline of the
volunteers
Clinical characteristics GS (n = 9) GP (n = 9)
Age (yr) 55.47
a ± 2.0 56,89
a ± 1.7
Height (m) 1.65
a ± 1.2 1.64
a ± 1.3
Weight (Kg) 75.43
a ± 2.01 75.89
a ± 2.00
BMI (Kg/m
2)* 27.70
a ± 0.78 28.21
a ± 0.85
Diabetes 9 9
Hypertension 7 8
Smoking 5 4
Energy (kcal/day) 2144.6
a ± 643.5 2322.4
a ± 543.5
Values are mean ± SD. Statistical comparison of groups: means with identical
minuscule letters in the same line do not differ significantly (P ≤ 0.05). GS
group symbiotic shake, GP group placebo shake, *BMI body massindex
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Lipid profile
Table 2 depict the results of the lipid profile of the S
Group (individuals who consumed the symbiotic shake)
and the P Group (individuals who consumed a placebo
shake) broken down over four distinct periods T0 (pre-
ingestion), T1 (10th day of ingestion), T2 (20th day of
ingestion) and T3 (30th day of ingestion).
The data contained in Table 2 show that after 4 weeks
of treatment, individuals that consumed the symbiotic
shake presented a reduction of 25.84% and 37.27% in
their serum total cholesterol and triglyceride levels,
respectively.
Three volunteers had levels of triglycerides above 400
mg/dl and therefore, we chose to calculate the concen-
tration of nHDL-C, which represents the potentially
atherogenic particles (LDL, IDL, VLDL) [13]. At the end
of the experiment the volunteers that ingested the sym-
biotic shake showed a significant reduction on n-HDL-
C, compared with the pre-treatment time (41.30%; p <
0.05).
With regard to HDL cholesterol (High density lipo-
protein) of the S and P groups over the experimental
period, a significant increase (35.15%; p < 0.05) was
observed in the group that consumed the symbiotic
shake (43.33 to 58.56 mg/dL).
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Assessed for eligibility (n=80  ) 
Excluded  (n=30   ) 
iNot meeting inclusion criteria (n=15 ) 
iDeclined to participate (n=10  ) 
iOther reasons (n=5  ) 
n=10/25(36%)
Reasonsfordiscontinuing
Moved:n=5
Unwillingtocontinue:n=11
Unknown:n=5
n=10/25(36%)
Analysis of serum cholesterol, triglycerides,  HDL cholesterol and  glycemia 
Randomized (n=50  ) 
Diet shake symbiotic  (n=25  )  Diet shake placebo  (n=25  ) 
Reasonsfordiscontinuing
Moved:n=5
Unwillingtocontinue:n=5
Unknown:n=11
Figure 1 Study design.
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period of time did not exhibit any significant change (p >
0.05) relative to the total cholesterol, HDL-C; n-HDL-C
and triglycerides concentration (4.69, 9.74, 11.35, 17.07%,
respectively).
Glycemia
Table 3 presents the levels of fasting glycemia levels for
the individuals that participated in the study. A significant
reduction (38.89%, p < 0.05) in glycemia (191.11 to 116.78
mg/dL) was observed over the course of the study in the
individuals who consumed the symbiotic shake. However,
no significant change (p > 0.05) was noted in the glycemia
levels of the indivuals who consumed the placebo shake.
Discussion
Changes in lifestyle, including a balanced diet and regular
physical exercise may be the first step towards reducing
LDL cholesterol and glycemia levels [14]. As for eating
habits in particular, the consumption of fermented foods,
fibers and oligosaccharides may contribute to reducing
cholesterol and glycemia [15]. Probiotic bacteria and pre-
biotics have been introduced into the gastrointestinal
tract through food matrices such as yogurts and cheeses
[10]. However, at present, efforts are directed towards
developing other, non-dairy foods to be used as food
matrix to deliver probiotics to the intestinal tract, includ-
ing shake [16] and cereal bars [17], among others. There
are several studies on the efficacy of the consumption of
probiotics on the reduction of blood cholesterol levels
[15,18], with some of these also reporting reduced glyce-
mia as a result of the regular intake of prebiotics [19,20].
However, the literature contains only few and fragmen-
tary data and information on the effect of probiotics and
prebiotics in elderly people. For that reason, the purpose
of the present study was to investigate and evaluate the
effect of the consumption of a symbiotic shake on the
lipid profile and glycemia in elderly people. To this pur-
pose, two periods were evaluated: (1) a pre-ingestion per-
iod (15 days prior to initiating the consumption of the
products); and (2) the ingestion period (30 days of con-
tinued consumption of the products).
At the end of the ingestion period, the volunteers that
received the symbiotic shake exhibited a reduction in total
cholesterol, n-HDL-C and triglycerides levels (25.84%,
41.30%; and 37.27%, respectively) and an increase on
HDL-C concentrations (35.15%). Similar findings were
reported by Larskin et al [15], who observed a reduction
in total cholesterol and triglycerides after 5 weeks inges-
tion of L. acidophilus and B. bifidum. However, Lewis et al
[21] did not observe any change in blood lipids in a dou-
ble-blind, placebo-controlled study investigating the effect
Table 2 Lipid profile of the symbiotic and placebo groups during pre-ingestion and ingestion of the symbiotic shake
Parameter T0 T1 T2 T3 Variation in the period T0-T3 (%)
Total Cholesterol (mg/dL)
Group S 229.67 ± 55.51
a 175.33 ± 49.09
b 188.22 ± 29.03
ab 170.33 ± 28.85
b -25.84% (p < 0.05)
Group P 204.00 ± 3.97
a 160.56 ± 19.94
a 194.67 ± 49.75
a 191.44 ± 33.78
a -4.69% (p > 0.05)
HDL-C (mg/dL)
Group S 43.33 ± 12,94
a 48.78 ± 13,10
a 51.11 ± 15.16
a 58.56 ± 11.08
a +35.15% (p > 0.05)
Group P 50.22 ± 18.30
a 49.22 ± 14.67
a 49.33 ± 18.72
a 55.11 ± 14.34
a +9.74% (p > 0.05)
nHDL-C (mg/dL)
Group S 190.44 ± 58.19
a 126.56 ± 43.00
b 137.11 ± 30.39
b 111.78 ± 24.68
b -41,30 (p < 0.05)
Group P 153.78 ± 18.21
a 111.33 ± 29.06
a 145.33 ± 59.96
a 136.33 ± 32.79
a -11.35 (p > 0.05)
Triglycerides (mg/dL)
Group S 317.56 ± 101.08
a 248.89 ± 62.95
ab 204.00 ± 89,90
b 199.22 ± 54,60
b -37.27% (p < 0.05)
Group P 239.44 ± 58.38
a 217.33 ± 56.47
a 226.33 ± 126.23
a 198.56 ± 66.07
a -17.07% (p > 0.05)
Means followed by the same lower case letters in the same line are not statistically different within the same group (P < 0.05)
T0: Pre-ingestion period, T1: 10th day of ingestion, T2: 20th day of ingestion, T3: 30th day of ingestion
Group S: Individuals who consumed the symbiotic shake
Group P: Individuals who consumed the placebo shake
Table 3 Effect of the consumption of a symbiotic shake
and a placebo shake on glycemia (mg/dL)
Period Group S Group P
T0 191.11 ± 18.31
a 136.78 ± 19.47
a
T1 128.56 ± 29.23
b 121.33 ± 1.00
a
T2 123.22 ± 27.78
b 110.11 ± 19.90
a
T3 116.78 ± 18.96
b 110.56 ± 29.90
a
Means followed by the same lower case letters in the same column are not
statistically different within the same group (P < 0.05)
T0: Pre-ingestion period, T1: 10th day of ingestion, T2: 20th day of ingestion,
T3: 30th day of ingestion
Group S: Individuals who consumed the symbiotic shake
Group P: Individuals who consumed the placebo shake
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levels. De Roos et al [22] also did not observe any signifi-
cant influence on the serum cholesterol of individuals who
had consumed yogurt enriched with Lactobacillus acido-
philus, though they did find statistically significantly higher
HDL cholesterol concentrations in these same individuals.
Similar results were observed by Kiebling et al [23], who
reported a significant increase in HDL cholesterol with the
administration of yogurt fermented by L. acidophilus 145
and B. logum 913 and added with 1% oligofructose. How-
ever, Greany et al [24], investigating capsules with combi-
nation of culture pure of L. acidophilus DDS-1, B. logum
UABL-14 and FOS, did not observe any significant eleva-
tion in HDL.
Although many studies demonstrate the positive effect
of prebiotics and probiotics on the modulation of serum
cholesterol levels [25,26], some of these studies report
conflicting findings and the mechanisms underlying the
modulation of serum cholesterol levels by symbiotics
remain largely obscure. According to Lee et al [27], five
mechanisms may be involved in the reduction of choles-
terol levels by lactic bacteria: (a) inhibition of the enzy-
matic synthesis of cholesterol by the fermentation
products of lactic bacteria, mainly short chain fatty
acids; (b) the bacteria may facilitate elimination of cho-
lesterol through the feces; (c) inhibition of cholesterol
absorption back into the body by binding with choles-
terol; (d) the bacteria may interfere with the recycling of
bile salts, facilitating their elimination. In this situation,
cholesterol is mobilized to produce bile salts, resulting
in a fall in blood cholesterol levels; (e) assimilation by
lactic acid.
According Ooi and Liong [28] some species of Lacto-
bacillus, Bifidobacterium, Enterococcus, and Streptococ-
cus have demonstrated to have the capacity of lowering
plasma cholesterol level. One of the underlying mechan-
isms is that these probiotic bacteria can reduce the reab-
sorption of bile acids through enterohepatic circulation.
This is due to the fact that conjugated bile acids but not
free forms are partly absorbed and directed back to the
liver. Live lactobacilli and bifidobacteria cells can hydro-
lyze the conjugated bile acids, excrete them faster and
reduce the extent to which they are reabsorbed.
In vitro experiments showed that probiotic bacteria,
including L. acidophilus spp. and B. bifidus may assimi-
late cholesterol and deconjugate bile salts. The probiotic
bacteria may assimilate dietary cholesterol, reducing
absorption and increase bile excretion [28]. However,
these effects are dependent on the ingestion of bacterial
strains capable of colonizing the small intestine where
cholesterol is absorbed [29].
In an earlier study it was evaluate the effect of the
same symbiotic product on fecal microbiota of elderly
people. The obtained results showed an increase in the
population of Bifidobacterium spp. and Lactobacillos
spp. (P < 0.01) and a decrease on Clostridium spp. and
Bacteroides spp. (P < 0.05) counts [16]. The modifica-
tion of the fecal microbiota composition observed dur-
ing the ingestion of the synbiotic shake could
collaborate to improve the lipid profile.
The effect of symbiotics on glycemia has not yet been
fully elucidated and the data available on this subject are
often somewhat contradictory, since they depend to a
large extent on the specific physiological conditions of
each individual. It is possible that, as is the case of other
fibers, fructooligosaccharides influence the absorption of
macronutrients, particularly carbohydrates, retard gastric
emptying and/or decrease small-bowel transit time. Gluco-
neogenesis induced by inulin and oligofructose may be
mediated by short-chain fatty acids, particularly propio-
nate [26]. In our study, we observed a significant reduction
in glycemia in the group that consumed the symbiotic
shake. The findings of our study are in accordance with
previously published data and reports in literature [30].
According to Luo et al [20] healthy volunteers who con-
sumed 20 g fructooligosaccharides for 4 weeks presented a
reduction of basal hepatic glucose production. In a clinical
study conducted by Cicek et al [2], diabetes type 2 volun-
teers who consumed 20 g oligofructose per day exhibited
a significant reduction in blood glucose levels after 6
weeks. According to Kaur & Gupta [31], inulin and oligo-
fructose modulate the hormonal level of insulin and also
the metabolism of carbohydrates and lipids by their ability
to lower blood sugar levels.
In our experiments, we observed a numerical reduction
in total cholesterol, a significant increase in HDL and a
significant decrease in glycemia in the volunteers that
ingested 200 mL/day of the symbiotic shake. No signifi-
cant change was observed in the volunteers that took the
placebo shake. A comparison between the results of our
study with findings reported in the literature reveals a
considerable number of discrepancies. According to
Manzoni et al [32], these discrepancies may be due to the
microorganism used, the volunteer population selected
for the study, the manner in which the probiotic is admi-
nistered and the duration of the protocol, with the posi-
tive effects being more evident in long-term protocols.
It should be noted that this study had some limitations
that will be considered in future studies. First, the study
population at the end of the protocol was small, since
some volunteers had health problems that impeded the
continuation of the study. The second limitation refers to
the fact that volunteers make use of oral hypoglycemic
agents and thus, the positive effects on blood glucose
levels cannot be attributed only to the symbiotic product.
However, since drug treatment was not able to maintain
blood glucose of the study population at normal levels,
could be attributed to the symbiotic shake a synergistic
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fication of short-chain fatty acids produced by intestinal
microbiota, using in vitro models, to relate to lipid-lower-
ing effects observed.
Conclusion
Based on the results obtained, it can be concluded that
regular consumption of 200 mL of symbiotic shake for
30 days resulted in a positive change in the lipid profile
and blood glucose level of the volunteers, and this pro-
duct could be used to assist in maintaining lipids and
glucose normal levels in the elderly population. None-
theless, more studies will be required to confirm the
effectiveness of the product.
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